Skip to content

PEELED INTERNAL LIMITING MEMBRANE REPOSITION

PEELED INTERNAL LIMITING MEMBRANE REPOSITION FOR IDIOPATHIC MACULAR HOLES: A Single-centre, Randomized, Prospective Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06359548
Enrollment
90
Registered
2024-04-11
Start date
2024-04-15
Completion date
2026-11-30
Last updated
2024-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macular Holes

Brief summary

Macular hiatus (MH) refers to a tissue defect in the photoreceptor cell layer of the inner boundary membrane of the optic disc in the macular region. Among them, idiopathic macular hiatus (IMH) is more common in people over 60 years old and is a common eye disease. With the aging of society, the number of patients increases, and it severely damages the patients' vision and life quality. Previously, the conventional surgical approach for treating MH was vitrectomy combined with inner limiting membrane (ILM) peeling. Although the closure rate of MH is high, many damages to the morphology and function of the ILM peeled area have been found. Our team firstly report a novel technique of peeled ILM reposition. Compared to traditional ILM peeling, the novel technique peeled ILM reposition maintains the integrity of internal retina by pull back the ILM flap. The previous pilot clinical study suggests that the novel technique peeled ILM reposition surgical intervention can achieve better morphology and functional prognosis. However, there is currently a lack of larger sample size prospective randomized controlled studies to further clarify the clinical efficacy of this new surgical technique in treating IMH. This study aims to conduct a single center, prospective, and randomized controlled study, combined with previous work, to analyze the efficacy of this novel technique peeled ILM peeling in the treatment of IMH. We hypothesize that this novel technique can achieved better morphological and functional prognosis compared to traditional ILM peeling.

Interventions

PROCEDUREPeeled ILM Reposition

The ILM was stained using 0.1 mL of indocyanine green(ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc) at a point away from the center of MH around one disc diameter in inferior quadrant of macular area. First, a horizontal ILM strip was peeled off with a width approximately 1.5 to 2.5 disc diameter. Then, the edge of the horizontal ILM strip was grasped and peeled from inferior to superior area continuously.Then the ILM roll was flattened back to peeled area assisted with approximately 1.0 mL of PFO (Perfluoron, Alcon Laboratories, Inc). The position of the fixed ILM flap was adjusted under PFO bubble using flute needle or forceps if required.

PROCEDUREILM Peeling

The ILM was stained using 0.1 mL of indocyanine green(ICG) for approximately 1minute after PPV. The ILM was grasped with end gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc). The strand of ILM was peeled off radially from the foveal center to the vascular arcade. As a result, a round-shaped, 2.5-disk diameter to 3.5-disk diameter ILM-peeled area was created.

Sponsors

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. The patients are diagnosed as MH with a diameter ≤ 600 µm by optical coherence tomography. 2. Age ranges from 50 to 80 years. 3. Do not participate in other clinical studies. 4. Agree to sign an informed consent form with good compliance.

Exclusion criteria

1. Traumatic macular hole. 2. Combined with serious epiretinal membrane. 3. Combined with diabetic retinopathy, hypertensive retinopathy. 4. Combined with other ocular diseases, such as keratitis,uveitis,retinal vasculitis. 5. Spherical equivalent ≥ -6.0 diopters or axial length ≥ 26 mm. 6. History of intraocular surgery. 7. Presence of staphyloma. 8. Other ocular diseases that influence macular microstructure or visual function.

Design outcomes

Primary

MeasureTime frameDescription
The change in the best corrected visual acuity (BCVA) from baseline to 6 months postoperativelyPre-operatively, 1-month postoperatively, 3-month postoperatively, 6-month postoperatively,The change of BCVA from baseline to 6-month postoperatively

Secondary

MeasureTime frameDescription
The range of inner retinal dimpling1-month postoperatively, 3-month postoperatively, 6-month postoperatively,The range of inner retinal dimpling was measured by OCT (RTVueXR Avanti; Optovue Inc, Fremont, CA)
Postoperative retinal thicknessPre-operatively, 1-month postoperatively, 3-month postoperatively, 6-month postoperatively,With the Thickness Map protocol of the OCT, the full retinal thickness (from ILM to retinal pigment epithelium), inner retinal thickness (from ILM to inner plexiform layer (IPL)), and outer retinal thickness (from IPL to retinal pigment epithelium) of the fovea, parafovea, and perifovea were recorded, respectively.
The fixation stability and sensitivity thresholdPre-operatively, 3-month postoperatively, 6-month postoperatively,Measured by microperimetry (MAIA, CenterVue, Italy)
The MH closure rate1-month postoperativelyThe MH closure rate at 1-month postoperatively
M-score valuesPre-operatively, 1-month postoperatively, 3-month postoperatively, 6-month postoperatively,Metamorphopsia score (M-score) measurement was performed using the M-chart (Inami Co, Tokyo, Japan)
NEI-VFQ-25 questionnaire scoresPre-operatively, 1-month postoperatively, 3-month postoperatively, 6-month postoperatively,The scores obtain from National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25 questionnaire)
mfERG P1 wave density amplitudesPre-operatively, 3-month postoperatively, 6-month postoperatively,Measured by multifocal electroretinogram (mfERG, Espion, Diagnosys LLC, Cambridge, United Kingdom)

Countries

China

Contacts

Primary ContactTian Tian, MD,PhD
tiantianoph@163.com+8615216695095

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026